Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients
|
|
- Ophelia Goodman
- 5 years ago
- Views:
Transcription
1 Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients Mary F Dillon 1,2, Anthony T Stafford 1, Gabrielle Kelly 3, Aisling M Redmond 1, Marie McIlroy 1, Thomas B Crotty 2, E McDermott 2, Arnold D Hill 1 and Leonie S Young 1 1 Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, St Stephens Green, Dublin 2, Ireland 2 UCD Conway Institute, School of Medicine and Medical Science, St Vincent s University Hospital and University College Dublin, Dublin, Ireland 3 School of Mathematical Sciences, Statistics and Actuarial Science, University College Dublin, Dublin, Ireland (Correspondence should be addressed to L S Young; lyoung@rcsi.ie) Abstract Cyclooxygenase-2 (COX-2) is associated with breast tumour progression. Clinical and molecular studies implicate human epidermal growth factor receptor 2 (HER2) in the regulation of COX-2 expression. Recent reports raise the possibility that HER2 could mediate these effects through direct transcriptional mechanisms. The relationship between HER2 and COX-2 was investigated in a cohort of breast cancer patients with or without endocrine treatment. A tissue microarray comprising tumours from 560 patients with 10-year follow-up was analysed for HER2, ERK1/2, polyoma enhancer activator 3 (PEA3) and COX-2 expression. Subcellular localisation of HER2 was assessed by immunofluorescence and confocal microscopy. Expression of markers examined was analysed in relation to classic clinicopathological parameters and disease-free survival in the presence and absence of tamoxifen. COX-2 expression associated with both membranous and nuclear expression of HER2 (PZ and P! respectively). No association was detected between COX-2 and either ERK1/2 or PEA3 (PZ0.7 and PZ0.3 respectively). None of the markers were found to be independently prognostic. Membrane HER2, nuclear HER2 and COX-2, however, were all found to predict poor disease-free survival in patients on endocrine treatment (PZ0.0017, PZ and PZ respectively). Moreover, patients who were positive for COX-2 predicted adverse effects of tamoxifen (PZ0.0427). These clinical ex vivo data are consistent with molecular observations that HER2 can regulate COX-2 expression through direct transcriptional mechanisms. COX-2 expression correlates with disease progression on endocrine treatment. This study supports a role for COX-2 as a predictor of adverse effects of tamoxifen in breast cancer patients. Endocrine-Related Cancer (2008) Introduction There is substantial evidence to suggest that cyclooxygenase-2 (COX-2), an enzyme that catalyses the formation of prostaglandins, is important in breast carcinogenesis. Expression of COX-2 is associated with parameters of disease progression, including size, positive lymph node metastasis and human epidermal growth factor receptor 2 (HER2)-positive status (Howe et al. 2001b, Ristimaki et al. 2002, Nassar et al. 2007). Furthermore, overexpression studies in mice suggest that COX-2 is important in the genesis of mammary tumours (Liu et al. 2001). COX-2-derived prostaglandins drive tumour growth through a number of mechanisms including, cell proliferation (Sheng et al. 2001), angiogenesis (Tsujii et al. 1998) and local invasion (Dohadwala et al. 2001). The tyrosine kinase receptor HER2 is amplified in 20 30% of human cancers and overexpression has been associated with poor patient prognosis (Ross & Fletcher 1998). Molecular and translational studies Endocrine-Related Cancer (2008) /08/ q 2008 Society for Endocrinology Printed in Great Britain Downloaded from Bioscientifica.com DOI: /ERC at 09/10/ :53:06PM Online version via
2 M F Dillon et al.: HER2 and COX-2 in endocrine-resistant breast cancer provide a substantial link between HER2 signalling and COX-2 expression in cancer (Ristimaki et al. 2002, Simeone et al. 2004). Significant associations between COX-2 and HER2 expression has been reported in human breast cancer (Hwang et al. 1998). The HER2 receptor can employ several second messenger signalling mechanisms, including the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase/protein kinase B (AKT) system (Moasser 2007). The Ets proteins are a family of MAPK-dependent transcription factors. The Ets member polyoma enhancer activator 3 (PEA3) is thought to play an essential role in HER2-mediated oncogenesis (Benz et al. 1997, Shepherd et al. 2001). We have recently reported strong associations between co-expression of PEA3 and HER2 and reduced disease-free survival in breast cancer patients (Myers et al. 2006). Several molecular studies suggest that PEA3 can transcriptionally regulate COX-2 (Howe et al. 2001a, Subbaramaiah et al. 2002). In HER2-transformed human mammary epithelial cells, HER2 can signal to PEA3 via the MAP kinase pathway to regulate COX-2 expression (Subbaramaiah et al. 2002). However, in a clinical study focusing on stage I breast cancer patients, no association was observed between COX-2 expression and implicated signalling pathways, including MAP kinase and AKT (Schmitz et al.2006). Although the function of HER2 as a transmembrane receptor has been well described recently, several studies provide evidence of a nuclear function as a transcriptional regulator (Xie & Hung 1994, Vadlamundi et al. 1999, Wang et al. 2004). Nuclear HER2 has been found to associate with multiple genomic targets, including the COX-2 gene promoter. HER2 can form a complex at specific nucleotide sequences within the COX-2 promoter to regulate gene transcription (Wang et al. 2004). These observations raise the possibility that in breast cancer cells HER2 can mediate its effects, at least in part, through direct transcriptional regulation of COX-2. In order to elucidate the relationship between HER2 and COX-2 in endocrine-treated breast cancer, we examined the expression of membrane HER2, nuclear HER2, the signalling mediator ERK1/2, the transcription factor PEA3 and COX-2 in a large cohort of patients. Materials and methods Patient information and construction of tissue microarray (TMA) Following ethical approval, breast tumour samples were obtained from archival cases at St Vincent s 746 University Hospital, Dublin, Ireland, over the period from 1987 to Patients received either no endocrine treatment (nz200; ER positive 68%) or tamoxifen (nz360; ER positive 74%), 20 mg/day for 5 years, which was discontinued only in those patients who suffered a relapse while on endocrine therapy. Excluded from the analysis were patients who did not have breast surgery, those who had neoadjuvant therapy or those whose tissue specimens were irretrievable. Data on the patients included pathological characteristics (tumour size, grade, lymph node status, oestrogen receptor status) as well as treatment with radiotherapy, chemotherapy or tamoxifen. Detailed 10-year follow-up data (median 7.72 years) was collected from the patients to determine diseasefree and overall survival. Archival tissue was attained on the patient population for the purposes of TMA construction. A haematoxylin eosin slide was used on all specimens to mark the site of carcinoma. Four 0.6 mm punch biopsies were taken from each specimen, and transplanted into a recipient block. The recipient block was cut into 5 mm sections, mounted on Superfrost Plus slides (BDH, Poole, UK) and baked in an oven for 1 h at 60 8C. Immunohistochemistry Sections were dewaxed, rehydrated and washed with PBS. Endogenous peroxidase activity was blocked by immersion in 3% hydrogen peroxidase (BDH) in distilled water for 20 min in the dark. Antigen retrieval was performed by immersing the sections in 0.01 M sodium citrate buffer (Sigma Aldrich) and microwaving on high power for 7 min and low power for 15 min. The sections were blocked in the appropriate serum (Sigma Aldrich) for 60 min. All the primary antibodies were diluted in PBS. The sections were incubated with primary antibodies as follows: mouse anti-human ERa (5 mg/ml) (cat no. sc-8002; Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit anti-human phospho-p44/42 MAPK (Thr202/Tyr204) (10 mg/ml) (cat no. 4376L; Cell Signalling Tech, Danvers, MA, USA), mouse anti-human PEA3 (50 mg/ml) (cat no. sc-113; Santa Cruz); mouse anti-human COX-2 (8 mg/ml) (cat no ; Cayman, Ann Arbor, MI, USA). The primary antibodies were incubated for 60 min at room temperature, except for anti-cox-2 antibody, which was incubated for 120 min, or anti-pea3 antibody, overnight at 4 8C. The sections are subsequently incubated with the corresponding biotin-labelled secondary (1:2000 in PBS) (Vector Laboratories, Burlingame, CA, USA) for
3 30 min, followed by peroxidase-labelled avidin biotin complex (Vector Laboratories) for 30 min. The sections were developed in 3,3 0 -diaminobenzidine tetrahydrochloride for 3 7 min and counterstained with haematoxylin for 2 min. The sections were then passed through increasing concentrations of industrial methylated spirits (70, 90 and 100%) for 5 min in each container and then xylene for 10 min. Immunostained slides were scored for phospho- ERK1/2, PEA3 and COX-2 using the Allred scoring system (Harvey et al. 1999). Independent observers, without knowledge of prognostic factors, scored slides. Assessment of HER2 status HER2 status was evaluated using the DAKO (Glostrup, Denmark) HercepTest immunocytochemical assay. Scoring was assessed in accordance with the manufacturer s instructions. A score was assigned according to the intensity and pattern of cell membrane staining: 0toC1, no staining or staining in!10% of cells; C2, weak-to-moderate staining in O10% of cells and C3, strong staining in O10% of cells. In tumour samples scoring C2 with the Hercep Test, the samples were selected out and a TMA constructed consisting of these tumours. HER2 status was confirmed by fluorescent in situ hybridisation using the PathVysion kit probe to detect amplification of the HER2 gene (spectrum orange-labelled HER2 and spectrum green-labelled a satellite centromeric region for chromosome 17) (Vysis Inc., Downers Grove, IL, USA), according to the manufacturer s instructions. Criteria for gene amplification were tight clusters of HER2 signals in multiple cells with at least two times more HER2 signal than centromeric 17. Immunofluorescent microscopy Breast cancer sections were prepared as above and incubated in goat serum for 60 min. Rabbit anti-human HER2 (10 mg/ml in 10% human serum, cat no. 2165; Cell Signalling Tech) was placed on each slide for 90 min. The sections were incubated with the corresponding secondary fluorochrome-conjugated antibody (1:100) (Sigma Aldrich) for 60 min. The sections were mounted using fluorescent mounting media (DAKO). The slides were examined under a confocal fluorescent microscope. Negative controls were performed by matched IgG (Rabbit IgG, cat no. X0903; DAKO). A score was assigned according to the intensity and pattern of nuclear staining: 0 to C1, no staining or staining in!10% of cells; C2, weakto-moderate staining in O10% of cells and C3, strong Figure 1 (A) Immunohistochemical localisation of HER2 (100!), with fluorescent in situ hybridisation of HER2 gene amplification (200!) (inset) and matched IgG control. (B) Immunofluorescent localisation of HER2 to the membrane (HER2m) (100!), (400!) and counterstained with DAPI (400!) (insets). Immunofluorescent localisation of HER2 to the membrane and nucleus (HER2m and HER2n) (100!), (400!) and counterstained with DAPI (400!) (insets). (C) Immunohistochemical localisation of phospho-erk1/2 (100!), (400!) (insets) with matched IgG control. (D) Immunohistochemical localisation of PEA3 (100!), (400!) (insets) with matched IgG control. (E) Immunohistochemical localisation COX-2 (100!), (400!)(insets) with matched IgG control
4 M F Dillon et al.: HER2 and COX-2 in endocrine-resistant breast cancer staining in O10% of cells. A score of R2 was considered positive. Statistical analysis Statistical analysis was carried out using Fisher s exact test for categorical variables to compare two proportions. Kaplan Meier estimates of survival functions were computed and the Wilcoxon test was used to compare survival curves. In addition, the Wilcoxon rank-sum test was used to compare two medians. Two-sided P values!0.05 were considered to be statistically significant. Results Localisation and expression of HER2, phospho-erk1/2, PEA3 and COX-2 in human breast cancer tissue The tyrosine kinase receptor HER2 was found to be expressed predominantly at the cell membrane (Fig. 1A). On immunohistochemical analysis, there was also notable nuclear staining in a large number of HER2-positive breast cancer patients. Immunofluorescence and confocal microscopy confirmed nuclear localisation of HER2 (Fig. 1B). Phospho-ERK1/2 was expressed in both the nucleus and the cytoplasm of the tumour epithelial cells, whereas COX-2 was found to be expressed primarily in the cytoplasm. PEA3 was found to be predominantly nuclear, with some scant staining observed in the cytoplasm (Fig. 1C E). Membrane and nuclear HER2 were expressed in 19.9 and 12.3% respectively of the total breast cancer patient population. The MAP kinase signalling mediator, phospho-erk1/2, was expressed in 30.3% of patients. PEA3 and COX-2 were detected in 53.1 and 47.8% of patients respectively (Table 1). Consistent with the theory that HER2 can signal to PEA3 to transcriptionally regulate COX-2 expression, there were significant associations between membrane HER2 and PEA3 (PZ0.0043) and membrane HER2 and COX-2 (PZ0.0033). However, no association was detected between either membrane HER2 and ERK1/2 (PZ0.51) or between PEA3 and COX-2 (PZ0.3) (Table 1). To elucidate the role of HER2 as a direct transcriptional regulator of COX-2 in breast cancer patients, we examined the relationship between nuclear HER2 and COX-2. Tumours that expressed HER2 in the nucleus of the cancer epithelial cells were significantly associated with expression of COX-2 (P! ) (Table 1). These data support a role for HER2 as a transcription factor important in the regulation of COX-2. An inverse association between ER expression and expression of Table 1 Associations of markers, HER2 membrane (HER2m), HER2 nuclear (HER2n), phospho-erk1/2, PEA3 and cyclooxygenase-2 (COX-2) expression with each other using Fisher s exact test PEA3 COX-2 Total (%) ER HER2m HER2n ERK1/2 ERCve !0.001 ERKve HER2mCve ! HER2mKve HER2nCve ! HER2nKve ERK1/2Cve ERK1/2Kve PEA3Cve PEA3 Kve COX-2Cve COX-2Kve
5 Table 2 Comparisons of HER2 membrane (HER2m), HER2 nuclear (HER2n), phospho-erk1/2, PEA3 and cyclooxygenase-2 (COX-2) expression with clinicopathological parameters using Fisher s exact test Total n HER2m HER2n P ERK1/2 PEA3 COX-2 % Positive patients % Axilla Positive % Negative % Size O2.5 cm % !2.5 cm % Grade O grade III % ! grade III % COX-2 and both membrane and nuclear HER2 was observed (PZ0.0013, PZ and PZ respectively, Table 1). Associations between expression of HER2, phospho-erk1/2, PEA3 and COX-2, and clinical variables in breast cancer patients Associations between the qualitative expression of membrane and nuclear HER2, phospho-erk1/2, PEA3 and COX-2 and clinicopathological parameters were examined (Table 2). Nuclear expression of HER2 and phospho-erk1/2 associated with tumour size (PZ and PZ0.006), whereas HER2 both at the membrane and in the nucleus was found to associate with tumour grade (PZ0.03 and PZ respectively). Tumours that expressed COX-2 were associated with lymph node positivity (PZ0.0448). HER2 and COX-2 expression and endocrine response The ability of HER2, phospho-erk1/2, PEA3 and COX-2 to act as prognostic factors or to predict response to endocrine therapy was examined. In patients who received no adjuvant treatment following primary surgery, there was no significant association between any of the markers and disease-free survival detected (Table 3; Fig. 2A (i iii)). In patients who received tamoxifen following initial surgery, expression of membrane HER2, nuclear HER2 and COX-2 was each associated with reduced disease-free survival (PZ0.0017, PZ and PZ respectively) (Fig. 2A (iv vi)). Furthermore, in the total patient population, co-expression of COX-2 and nuclear HER-2 significantly increased the rate of recurrence, compared with patients who expressed COX-2, but not nuclear HER-2 (PZ0.0289) (Fig. 2B). However, in patients on tamoxifen treatment, co-expression of COX-2 with any of the markers examined did not impact on disease-free survival compared with COX-2 alone. Association between PEA3 and poor disease-free survival on endocrine treatment approached significance (PZ0.0672), whereas no association between expression of phospho-erk1/2 and response to treatment was observed (Table 3). As expression of membrane HER2, nuclear HER2 and COX-2 all associated with reduced disease-free survival in patients who received adjuvant tamoxifen, we examined the impact of treatment on patients who were positive for each of these markers. Although patients who expressed either membrane HER2 or nuclear HER2 had a reduced disease-free survival when treated with tamoxifen compared with patients who received no treatment according to Kaplan Meier estimates of survival, these data did not reach statistical significance (PZ0.331 and PZ0.143 respectively) (Fig. 3A and B). However, in patients who were positive for COX-2, those who were treated with tamoxifen, did significantly worse compared with patients who received no adjuvant endocrine treatment (PZ0.0427) (Fig. 3C). Table 3 Correlation of HER2 membrane (HER2m), HER2 nuclear (HER2n), phospho-erk1/2, PEA3 and cyclooxygenase-2 (COX-2) expression with disease-free survival using Wilcoxon test Time to recurrence no endocrine treatment P value Time to recurrence patients treated with tamoxifen P value HER2m HER2n ERK1/ PEA COX
6 M F Dillon et al.: HER2 and COX-2 in endocrine-resistant breast cancer Figure 2 Kaplan Meier estimates of disease-free survival (DFS). (A) DFS of breast cancer patients who received no endocrine therapy according to HER2 membrane (i), HER2 nuclear (ii) and COX-2 (iii) expression and corresponding patient populations treated with tamoxifen (iv vi). (B) DFS according to HER2 nuclear expression in COX-2-positive breast tumour patients. Discussion COX-2 has been shown to participate in tumour development and progression. Its actions are mediated, at least in part, by increased angiogenesis and CD44- induced invasion (Tsujii et al. 1998, Hiscox et al. 2006). In this clinical ex vivo investigation, we examined the contribution of COX-2 to tumour progression and resistance to endocrine treatment and investigated the role of HER2 in regulating COX-2 expression. Clinical and molecular studies provide a strong link between the tyrosine kinase receptor HER2 signalling and regulation of COX-2 expression. In this study, we found strong associations between expression of the membrane receptor and COX-2 in breast tumour tissue. 750 Evidence from in vitro work suggests that HER2 induces COX-2 expression via activation of ERK1/2, JNK and p38 (Subbaramaiah et al. 2002). Transcriptional upregulation of the COX-2 gene by HER2 expression has been found in cultured cancer cells (Howe et al. 2001b, Subbaramaiah et al. 2002). In HER2-transformed human mammary epithelial cells, HER2 has been shown to regulate COX-2 expression via MAP kinase-induced activation of the transcriptional regulator PEA3 (Subbaramaiah et al. 2002). Clinical studies, however, in a cohort of stage I breast cancers failed to detect a relationship between COX-2 expression and activated AKT, ERK1/2, p38 and HER2 (Schmitz et al. 2006). In this ex vivo study, we examined the association between HER2 and
7 Figure 3 Kaplan Meier estimates of disease-free survival (DFS). DFS of breast cancer patients with and without tamoxifen treatment according to (A) HER2 membrane, (B) HER2 nuclear and (C) COX-2 expression. COX-2 regulation in a large breast cancer patient population. Although we found strong associations between membrane HER2 and the transcription factor PEA3, and its putative target COX-2, no association between HER2 and its second messenger signalling mediator phospho-erk1/2 was observed. Furthermore, there was no relationship detected between PEA3 and COX-2. These data suggest that in the clinical setting HER2-induced PEA3 regulation of COX-2 may not be important. However, although no association was observed immunohistochemically, this may not reflect mechanisms operating at a subcellular level that could have some clinical implications. Although the function of HER proteins as transmembrane growth factor receptors has been well documented, a nuclear function as a transcription factor is rapidly being established. Recent molecular studies provide evidence that HER2 can directly regulate COX-2 expression through transcriptional induction (Vadlamundi et al. 1999, Wang et al. 2004). The significance of this nuclear role for HER2 in terms of its ability to directly regulate COX-2 in a clinical setting and to promote tumour progression has not been investigated. In line with our findings for membrane HER2, no association was detected between nuclear HER2 and phospho-erk1/2. Very strong associations were observed, however, between nuclear HER2 and 751
8 M F Dillon et al.: HER2 and COX-2 in endocrine-resistant breast cancer COX-2 expression. The association was substantially greater than that detected between membrane HER2 and COX-2. These observations support a function for HER2 as a transcription factor important in the regulation of COX-2 in breast cancer patients. Several clinical studies have reported a role for COX-2 in tumour progression and reduced disease-free survival (Ristimaki et al. 2002, Denkert et al. 2003, Wülfing et al. 2003). Many of these investigations, however, did not take into account the influence of adjuvant endocrine therapies. Despite the lack of clinical data relating COX-2 expression to response to hormonal therapy, several studies provide indirect evidence of a role for the cyclooxygenase in endocrine resistance. Prostaglandins, in particular PGE2, enhance stromal aromatase production, suggesting crosstalk between the cyclooxygenase and steroid pathways (Zhao et al. 1996, Brueggemeier et al. 1999). Here, we stratified our patient population into those who received no adjuvant endocrine treatment and those who received tamoxifen for a 5-year period. The ability of HER2, phospho-erk1/2, PEA3 and COX-2 to act as either prognostic factors or to predict response to endocrine treatment was assessed. None of the markers examined were found to be independently prognostic. Membrane HER2, nuclear HER2 and COX-2, however, were all found to predict poor disease-free survival in patients on endocrine treatment. Although strong associations between COX-2 and nuclear HER2 in our total patient population suggest that nuclear HER2 may have a role to play in the production of COX-2 in breast cancer patients, in endocrine-treated patients, co-expression of COX-2 with nuclear HER2 did not impact on disease-free survival compared with COX-2 alone. These data suggest that expression of COX-2 in the endocrine setting may be regulated by alternative mechanisms. In determining the consequence of treatment with endocrine therapy in patients who express membrane HER2, nuclear HER2 and COX-2, we found that COX-2 positivity can predict an adverse effect of tamoxifen. In summary, data presented in this ex vivo study supports a role for HER2 in the direct transcriptional regulation of COX-2 in human breast cancer. COX-2 positivity in our patient population predicts adverse effects of hormonal therapy. Declaration of interest The authors declare that there is no conflict of interest that would prejudice the impartiality of this work. 752 Funding This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. Acknowledgements The authors wish to thank Prof. Niall O Higgins, St Vincent s University Hospital, Dublin, for his invaluable clinical expertise. Irish Foundation for Breast Diseases and Breast Cancer Ireland. References Benz CC, O Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A et al HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE & Robertson FM 1999 Correlation of aromatase and cyclooygenase gene expression in human breast cancer specimens. Cancer Letters Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H et al Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK & Dubinett SM 2001 Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. Journal of Biological Chemistry Harvey JM, Clark GM, Osborne CK & Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D & Nicholson RI 2006 Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. International Journal of Cancer Howe LR, Howard CC, Subbaramaiah K, Hassell JA, Dannenberg AJ & Brown AMC 2001a PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. Journal of Biological Chemistry Howe LR, Subbaramaiah K, Brown AM & Dannenberg AJ 2001b Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer
9 Hwang D, Scollard D, Byrne J & Levine E 1998 Expression of cyclooxygenase -1 and cyclooxygenase-2 in human breast cancer. Journal of the National Cancer Institute Liu CH, Chang SH, Narko K et al Overexpression of cyclooxygenase-2 is sufficient to induce tumrigenesis in transgenic mice. Journal of Biological Chemistry Moasser MM 2007 The oncogene HER2: its signalling and transforming functions and its role in human cancer pathogenesis. Oncogene Myers E, Hill AD, Kelly G, McDermott EW, O Higgins NJ & Young LS 2006 positive role for PEA3 in HER2- mediated breast tumour progression. British Journal of Cancer Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G & Cohen C 2007 COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Applied Immunohistochemistry and Molecular Morphology Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H & Isola J 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research Ross JS & Fletcher JA 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist Schmitz KJ, Callies R, Wohlschlaeger J, Kimming R, Otterbach F, Bohr J, Lee SH, Takeda A, Schmid RW & Baba HA 2006 Overexpression of cyclooxygenase-2 is an independent predictor of unfavourable outcome in nodenegative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with HER2/neu signalling pathways. Journal of Clinical Pathology Sheng H, Shao J, Washington MK & DuBois RN 2001 Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. Journal of Biological Chemistry Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ & Hassell JA 2001 The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Current Biology Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M & Tari AM 2004 Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Research Subbaramaiah K, Norton L, Gerald W & Dannenberg AJ 2002 Cyclooxygenase-2 is overexpressed in HER-2/neupositive breast cancer. Journal of Biological Chemistry Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M & DuBois RN 1998 Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell Vadlamundi R, Mandal M, Adam L, Steinbach G, Mendelsohn J & Kumar R 1999 Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene Wang SC, Lein HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F et al Binding at and transcription activation of COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, Rody A, Greb RR, Böcker W & Kiesel L 2003 Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. Journal of Cancer Research and Clinical Oncology Xie Y & Hung MC 1994 Nuclear localisation of p185neu tyrosine kinase and its association with transcriptional activation. Biochemical and Biophysical Research Communications Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 armoatase gene. Endocrinology
T he HER2 gene encodes a receptor tyrosine kinase that is
1069 ORIGINAL ARTICLE Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 F J Fleming, E Myers, G Kelly, T B Crotty, E W McDermott, N J O
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationThe importance of COX-2 expression as prognostic factor in early breast cancer
JBUON 2013; 18(3): 579-584 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE The importance of COX-2 expression as prognostic factor in early breast
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationHypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients
Journal of BUON 17: 663-668, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor
More informationSupplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the
Supplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the genome-wide methylation microarray data. Mean ± s.d.; Student
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationCorrelation between COX-2 Expression and Hormone Receptors in Invasive Ductal Breast Cancer
J Korean Surg Soc 2010;78:140-148 DOI: 10.4174/jkss.2010.78.3.140 원 저 Correlation between COX-2 Expression and Hormone Receptors in Invasive Ductal Breast Cancer Departments of Breast and Endocrine Surgery
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationAndrogen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations
Anatomic Pathology / ANDROGEN RECEPTOR IN BREAST CANCER Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations S. Nicholas Agoff,
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More information(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)
Supplementary Figure 1. Functional enrichment analyses of secretomic proteins. (a) Significant biological processes (upper panel) and disease biomarkers (lower panel) 2 involved by hrab37-mediated secretory
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationIMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA
& IMMUNOHISTOCHEMICAL EXPRESSION OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 (TIMP-1) IN INVASIVE BREAST CARCINOMA Suada Kuskunović*, Svjetlana Radović, Mirsad Dorić, Ajna Hukić, Mirsad Babić, Ivana Tomić,
More informationStat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer
Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer H Yamashita, M Nishio, Y Ando, Z Zhang, M Hamaguchi, K Mita, S Kobayashi, Y Fujii
More informationImmunostaining was performed on tumor biopsy samples arranged in a tissue-microarray format or on
Supplemental Methods Immunohistochemical Analyses Immunostaining was performed on tumor biopsy samples arranged in a tissue-microarray format or on prostatectomy sections obtained post-study. Briefly,
More informationThe role of oestrogen receptor a in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2
Endocrine-Related Cancer (2) 7 255 264 The role of oestrogen receptor a in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2 Dara O Kavanagh, Marie McIlroy,2,
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationDiabetes Mellitus and Breast Cancer
Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationAnnals of Diagnostic Pathology 10 (2006)
Annals of Diagnostic Pathology 10 (2006) 327 332 The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationHORMONE RECEPTOR EXPRESSION IN MALE BREAST CANCERS
March 5 Volume 9, Number 1 GHANA MEDICAL JOURNAL HORMONE RECEPTOR EXPRESSION IN MALE BREAST CANCERS * A.B. AKOSA, S. VAN NORDEN 1 AND Y. TETTEY Department of Pathology, University of Ghana Medical School,
More informationDetermination of HER2 Amplification by In Situ Hybridization. When Should Chromosome 17 Also Be Determined?
Anatomic Pathology / FISH f o r HER2: Wh e n to Use Ch r o m o s o m e 17 Determination of HER2 Amplification by In Situ Hybridization When Should Chromosome 17 Also Be Determined? John M.S. Bartlett,
More informationExpression and Significance of GRP78 and HER-2 in Colorectal Cancer
Expression and Significance of GRP78 and HER-2 in Colorectal Cancer Qiu-xia Ji 1, Li-li Wang 2, Lin Li 3, Xiaoming Xing 2 1 Department of Pathology, Qingdao University, Qingdao, China 2 Department of Pathology,
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Prognostic value of HER2/neu expression in patients with prostate cancer:
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationT he HER2/neu type 1 tyrosine kinase growth factor
710 ORIGINAL ARTICLE HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationClinicopathological significance of oestrogen receptor expression in non-small cell lung cancer
Research Report Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer Journal of International Medical Research 2017, Vol. 45(1) 51 58! The Author(s) 2016 Reprints
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationStudy on the Expression and Significance of TGF-β1, p-erk1/2and K-ras in Colorectal Cancer Using Tissue Microarray Technique
Clin Oncol Cancer Res (2011) 8: 21-26 DOI 10.1007/s11805-011-0554-z 21 Study on the Expression and Significance of TGF-β1, p-erk1/2and K-ras in Colorectal Cancer Using Tissue Microarray Technique Xin HU
More informationTamoxifen-induced ER-a SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence
Endocrine-Related Cancer (26) 13 11351145 Tamoxifen-induced ER-aSRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence Marie Mc Ilroy 1,2, Fergal
More informationTITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.
AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School
More informationHER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
Original article Annals of Oncology 13: 1398 1403, 2002 DOI: 10.1093/annonc/mdf217 HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationHER2/neu Evaluation of Breast Cancer in 2019
HER2/neu Evaluation of Breast Cancer in 2019 A.A. Sahin, M.D. Professor of Pathology and Translation Molecular Pathology Section Chief of Breast Pathology ERBB2 (HER2) Background 185-kDa membrane protein
More informationFang et al. NMuMG. PyVmT unstained Anti-CCR2-PE MDA-MB MCF MCF10A
A NMuMG PyVmT 16.5+.5 47.+7.2 Fang et al. unstained Anti-CCR2-PE 4T1 Control 37.6+6.3 56.1+.65 MCF1A 16.1+3. MCF-7 3.1+5.4 MDA-M-231 42.1+5.5 unstained Secondary antibody only Anti-CCR2 SUPPLEMENTAL FIGURE
More informationBreast cancer in Brunei Darussalam Differential community distribution and an analysis of common molecular tumour markers
Breast cancer markers Breast cancer in Brunei Darussalam Differential community distribution and an analysis of common molecular tumour markers Foo Ren Kang, PU Telesinghe, Syaffiq bin Abdallah, and R.
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationKEY WORDS: Breast carcinoma, c-erbb2, Fluorescent. Mod Pathol 2001;14(11):
HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization Thomas A. Thomson, M.D., Malcolm M. Hayes,
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationCitation Acta Medica Nagasakiensia. 1992, 37
NAOSITE: Nagasaki University's Ac Title Author(s) A Study on the Expression of EGFR a Content in the Stomach Cancer Tissu Nakazaki Takayuki Citation Acta Medica Nagasakiensia. 1992 37 Issue Date 1992-12-25
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationHer-2/neu expression and its correlation with ER status and various clinicopathological parameters
Original Research Article DOI: 10.5958/2394-6792.2016.00106.X Her-2/neu expression and its correlation with ER status and various clinicopathological parameters Kriti Chauhan 1,*, Monika Garg 2, Abhimanyu
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationISPUB.COM. C Choccalingam, L Rao INTRODUCTION ESTROGEN AND PROGESTERONE RECEPTORS
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 1 Learning Experience In Immunohistochemical Reporting Of Breast Cancer At A Rural Tertiary Hospital In India: A Comparison In Initial And Reviewed
More informationThe role of ERalpha in human thyroid cancer: contributions from coregulatory
Page 1 of 22 Accepted Preprint first posted on 23 December 2009 as Manuscript ERC-09-0216 The role of ERalpha in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor
More informationComparison of in situ hybridization methods for the assessment of HER-2/neu gene amplification status in breast cancer using a tissue microarray
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 44 49 Available online at www.sciencedirect.com jo u r n al hom epage: http://www.elsevier.com/locate/rpor Original article Comparison of
More informationRCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer
JBUON 2019; 24(2): 715-719 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE RCD24, B7-H4 and PCNA expression and clinical significance in ovarian
More informationSSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.
Supplementary Figure 1 SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer. Scatter plots comparing expression profiles of matched pretreatment
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationProgress in Experimental Tumor Research
COX-2 Progress in Experimental Tumor Research Vol. 37 Series Editor Joseph R. Bertino, New Brunswick, N.J. Basel Freiburg Paris London New York Bangalore Bangkok Singapore Tokyo Sydney COX-2 A New Target
More informationW omen under 35 years of age form only a small
323 ORIGINAL ARTICLE Immunohistochemical prognostic index for breast cancer in young women I Guerra, J Algorta, R Díaz de Otazu, A Pelayo, J Fariña... See end of article for authors affiliations... Correspondence
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationSupplementary Table 1. Characterization of HNSCC PDX models established at MSKCC
Supplementary Table 1. Characterization of HNSCC PDX models established at MSKCC Supplementary Table 2. Drug content and loading efficiency estimated with F-NMR and UV- Vis Supplementary Table 3. Complete
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationExpression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease
JBUON 2014; 19(2): 430-434 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com ORIGINAL ARTICLE Expression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease
More informationSupplementary Information
Supplementary Information Prognostic Impact of Signet Ring Cell Type in Node Negative Gastric Cancer Pengfei Kong1,4,Ruiyan Wu1,Chenlu Yang1,3,Jianjun Liu1,2,Shangxiang Chen1,2, Xuechao Liu1,2, Minting
More informationLow phosphorylation of estrogen receptor a (ERa) serine 118 and high phosphorylation of ERa serine 167 improve survival in ER-positive breast cancer
Low phosphorylation of estrogen receptor a (ERa) serine 118 and high phosphorylation of ERa serine 167 improve survival in ER-positive breast cancer Hiroko Yamashita, Mariko Nishio, Tatsuya Toyama, Hiroshi
More informationComparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis
SHORT THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.) Comparative Analysis of Methods Used in Breast Cancer HER2 and Sentinel Lymph Node Diagnosis by Monika Francz MD Supervisor: Zoltán Szöllősi
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationEndocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre
Endocrine-Related Cancer (2006) 13 251 255 Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre K L Cheung, R Owers
More informationClinico-pathological significance of extra-nodal spread in special types of breast cancer
Cancer Biol Med 2014;11:116-122. doi: 10.7497/j.issn.2095-3941.2014.02.006 ORIGINAL ARTICLE Clinico-pathological significance of extra-nodal spread in special types of breast cancer Ecmel Isik Kaygusuz,
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationRoles of the AIB1 protein in the proliferation and transformation of human esophageal squamous cell carcinoma
Roles of the AIB1 protein in the proliferation and transformation of human esophageal squamous cell carcinoma L. Li 1 *, P. Wei 2 *, M.-H. Zhang 1, W. Zhang 2, Y. Ma 1, X. Fang 1, C.-L. Hao 1 and Z.-H.
More informationExpression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma
Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma H.B. Liu, Y. Zhu, Q.C. Yang, Y. Shen, X.J. Zhang and H. Chen Department of Pathology First People s Hospital
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More informationNHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma
Saponaro et al. Journal of Experimental & Clinical Cancer Research (2018) 37:96 https://doi.org/10.1186/s13046-018-0766-7 RESEARCH NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma
More informationThe expression and significance of tumor associated macrophages and CXCR4 in non-small cell lung cancer
JBUON 2018; 23(2): 398-402 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE The expression and significance of tumor associated macrophages and
More informationEvaluation of c-erbb-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett s adenocarcinoma
25 Evaluation of c-erbb-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett s adenocarcinoma Axel Walch a,, Karin Bink b, Peter Gais a, Stefan Stangl a, Peter Hutzler a, Michaela Aubele
More informationPatterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma
Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma Hadia. Mohammed. Abdalla. Abdalrhman *, Elsadig.A.Adam, Ayda.D.A.Allatif 3,'Namareg.E.Afadul
More informationSupplementary Figure 1: Neuregulin 1 increases the growth of mammary organoids compared to EGF. (a) Mammary epithelial cells were freshly isolated,
1 2 3 4 5 6 7 8 9 10 Supplementary Figure 1: Neuregulin 1 increases the growth of mammary organoids compared to EGF. (a) Mammary epithelial cells were freshly isolated, embedded in matrigel and exposed
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationHigher expression of deoxyuridine triphosphatase (dutpase) may predict the metastasis potential of colorectal cancer
1 Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan; 2 Department of Surgery, Kurume University School of Medicine, Kurume, Japan; 3 Biostatistics Center, Kurume University,
More informationModified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast
British Journal of Cancer (2011) 105, 698 708 All rights reserved 0007 0920/11 www.bjcancer.com Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma
More informationPriti Lal, MD, 1 Paulo A. Salazar, 1 Clifford A. Hudis, MD, 2 Marc Ladanyi, MD, 1 and Beiyun Chen, MD, PhD 1. Abstract
Anatomic Pathology / DUAL- VS SINGLE-COLOR SCORING IN IMMUNOHISTOCHEMICAL AND FISH HER-2 TESTING HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ Hybridization
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationClinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
Yang et al. World Journal of Surgical Oncology (2018) 16:51 https://doi.org/10.1186/s12957-018-1332-7 RESEARCH Open Access Clinical significance and prognostic value of receptor conversion in hormone receptor
More informationInverse relationship between ER-b and SRC-1 predicts outcome in endocrine-resistant breast cancer
British Journal of Cancer (2004) 91, 1687 1693 All rights reserved 0007 0920/04 $30.00 www.bjcancer.com Inverse relationship between ER-b and SRC-1 predicts outcome in endocrine-resistant breast cancer
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationClinical utility of cancer biomarkers assessed by virtual microscopy
Clinical utility of cancer biomarkers assessed by virtual microscopy Lina Seiz Clinical Research Unit Head: Prof. Dr. Manfred Schmitt Department of Obstetrics and Gynecology Klinikum rechts der Isar Established
More informationSupplemental Information
Supplemental Information Tobacco-specific Carcinogen Induces DNA Methyltransferases 1 Accumulation through AKT/GSK3β/βTrCP/hnRNP-U in Mice and Lung Cancer patients Ruo-Kai Lin, 1 Yi-Shuan Hsieh, 2 Pinpin
More informationPAX6 overexpression is associated with the poor prognosis of invasive ductal breast cancer
ONCOLOGY LETTERS 10: 1501-1506, 2015 PAX6 overexpression is associated with the poor prognosis of invasive ductal breast cancer XIANGHOU XIA 1, WENJUAN YIN 2, XIPING ZHANG 1, XINGFEI YU 1, CHEN WANG 1,
More informationTumor Angiogenesis in Stage II Colorectal Carcinoma Association With Survival
ANATOMIC PATHOLOGY Original Article Tumor Angiogenesis in Stage II Carcinoma Association With Survival BARBARA F. BANNER, MD, ROB WHITEHOUSE, STEPHEN P. BAKER, MSPH, AND RICHARD S. SWANSON, MD We studied
More informationAstrocyte Elevated Gene 1 (AEG-1): A Promising Candidate for Molecular Targeted Therapy in Oral Squamous Cell Carcinomas
DOI:10.22034/APJCP.2017.18.12.3301 RESEARCH ARTICLE Astrocyte Elevated Gene 1 (AEG-1): A Promising Candidate for Molecular Targeted Therapy in Oral Squamous Cell Carcinomas Maryam Seyedmajidi 1, Shabnam
More information